Connect with us

Stock Market Sectors

Utility Stocks To Take Notice Of 2 Good; 1 Bad

Joe Samuel



Utility Stock Price

Investing in utility stocks is usually a boring event, with the spotlight normally shining on reliable quarterly dividend payments. New developments at SCANA Corporation (NYSE: SCG) have been anything but mundane. Dominion Energy could be the company’s shining star, but not if the government has its way.

For this reason, investors may be better off putting their money in high-yielding Duke Energy Corporation (NYSE: DUK) or PPL Corporation (NYSE: PPL).

What Does The Future Hold?

SCANAhasn’t really gotten great news. Its project was hit with cost overruns and delays, and this led to a lot of bad press and growing relationship with key stakeholders that became tense. That resulted in SCANA halting nuclear construction altogether.

Without regulatory relief, SCANA could have a difficult time staying viable thanks to the debt related to the now-canceled nuclear plant. It has already been mandated to cut its dividend by 80%. Bigger utility company Dominion Energy has jumped into the outer margins, offering to buy SCANA, but the deal needs approval.

The issue is that some stakeholders are complaining about the deal. So the best outcome is that SCANA gets brought into the fold of Dominion. The worst case is investors will own a very troubled utility that may not survive its nuclear issues.

Some Options

This is where Duke Energy enters stage left. This utility dropped its nuclear plans before they fell apart and took the company with it.  Furthermore, the construction troubles it had at a clean coal plant are now in the rearview mirror. In fact, it has revamped its entire business in recent years, shedding carbon-based retail power assets and foreign operations, picking up a natural gas utility, and growing its reach in renewable power.

It has plans to spend roughly $37 billion across its various businesses between 2018 and 2022. This spending, roughly 90% of which will be on regulated assets, should help it get approval for rate hikes and support the company’s projection of 4% to 6% annual earnings and dividend growth over that span. That’s not exciting, but it’s got a high chance of hitting these targets since the spending is for necessary upgrades and equipment that are not controversial in any way. And with a strong 4.4% yield, investors are getting an above market yield backed by what should be inflation-beating dividend growth.

But there’s more and it deals with currency fluctuations that are likely to wash out over the long term. And the added diversification of the UK assets could be viewed as a net positive as the energy sector continues to evolve — note that oil giants Total and Royal Dutch Shell have been investing in electric assets lately. And those pesky coal plants, well, they need to be replaced over time, which is exactly the type of spending that regulators like to see when considering rate hikes. So far from being a negative, the company’s need to upgrade its asset base should probably be seen as a net positive.

The dividend, meanwhile, should continue to expand, though only in the low single digits. However, over the last decade, annualized distribution growth has basically kept pace with the historical average for inflation growth, ensuring that investors’ buying power hasn’t been eroded. Investors looking to maximize current income should do a deep dive at PPL.

Continue Reading
Click to comment


Biotech Names To Know In November 2019

A. Lawrence



best biotechnology stocks to buy sell

Biotech Stocks Have rallied since The End Of September; What’s Next?

Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.

In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.

Sernova Corp’s (TSX:SVA) (OTC:SEOVF)

Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,

Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”

Read This Full Press Release Here

Genprex (GNPX)

The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.

The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.

 Can Fite Biopharma (CANF)

The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.

The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.

top biotech stocks to watch list

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading


Is The Entertainment Streaming Market Ready For Its Next Move?

A. Lawrence



streaming wars netflix apple hulu disney

New Streaming Options Have Opened A Big Door For Content Providers

As many experts have pointed out, the end of 2019 is going to see the commencement of the ‘streaming wars’ as more and more companies enter the OTT market to challenge the supremacy of Netflix Inc (NASDAQ:NFLX). The launch of the streaming service Disney Plus last week formally launched the streaming wars.

Do Content Providers Stand To Benefit?

According to an article published on Reuters the global video streaming market was valued at $26.27 billion in 2015 and is expected to reach $83.41 billion by 2022 growing at a CAGR of 17.9% from 2015 to 2022. Apple, Disney, Netflix, Amazon, NBC, Hulu & more are all competing within the global video streaming market and they all need the same thing… new & original content. Massive demand may create a huge opportunity for companies like Fearless Films (FERL).

Fearless Films is an independent full-service production company. This is the exact type of company that can benefit from what could become one of the biggest cash grabs in entertainment history and here’s why. You’ve likely heard of the big production houses: Warner Bros, DreamWorks, Red Crown Productions and others who benefited from big deals with streaming companies.

It isn’t just Netflix who’s flexing billions in content budgets, Apple, Amazon, Disney, NBC, Roku – the list goes on. These are huge entertainment distributors who are now fighting for one thing… Where you spend your waking hours streaming entertainment.

Click To Read More On Fearless Films (FERL)

Key Analysis On Streaming Service Providers

Considering the fact that the new service has already garnered 10 million users, it’s fair to say that it is here to say. Considering the fact that Apple has already launched its own service and many other services are going to be launched in the next few months, experts are now wondering whether the streaming space has become too crowded.

The success of Game of Thrones has ushered in an era of unprecedented spending for quality content. The show generated total profit to the tune of $2.2 billion for HBO, which is owned by AT&T. Hence, video streaming companies have also decided to spend jaw-dropping sums on original content. Apple has earmarked $6 billion for original content, while Disney is expected to match that.

streaming cord cutting entertainment stocks

Both companies are trying to create that one show that could turn into a cash cow. On the other hand, Apple is going to price is monthly subscription at $4.99 and Disney is going to charge $6.99 for the same. In such a situation, one can expect Netflix to change tack since its cheapest subscription is worth $12.99.

So, the crowding is quite apparent as mega corporations enter the streaming space. However, the question remains whether the business is going to grow and new subscribers are going to flock in. Studies suggest that it will grow and up until 2024, the streaming market should grow by 18.8% each year. In 2024, the market is going to be worth $687 billion. Hence, it is quite clear that despite the intense competition that is going to come to the streaming space, there is still room for companies to grow and become profitable.

apple tv cord cutting AAPL stock

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.

Continue Reading


The Biotech Index Just Hit New Highs; Stocks To Watch

Joe Samuel



biotechnology stocks to watch

The Biotech ETF – IBB – Just Made New November Highs, What’s Next?

Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.

However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

What Happened This Week?

top biotech stocks to buy

This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”

The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.

“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner

NovaBay Pharmaceuticals (NBY)

The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.

The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.

REPORT: 1 Biotech Stock is Positioning Itself for Success

BioCryst Pharmaceuticals (BCRX)

Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.

In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.

REPORT: 1 Biotech Stock is Positioning Itself for Success

make money with penny stocks biotech

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!

Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (


Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact